Dawn O'Connell (Michael Brochstein/Sipa USA/Sipa via AP Images)

Covid-19 roundup: Mod­er­na, US sign con­tract for au­tumn boost­er dos­es; Enan­ta touts PhI re­sults for its an­tivi­ral

The US gov­ern­ment has placed a con­tract for 66 mil­lion dos­es of Mod­er­na’s Covid-19 vac­cine boost­er can­di­date, and the deal could bal­loon to an­oth­er 234 mil­lion dos­es.

The con­tract in­cludes up to $1.74 bil­lion for Mod­er­na to man­u­fac­ture and de­liv­er the dos­es of the bi­va­lent vac­cine can­di­date, dubbed mR­NA-1273.222. The shot con­tains anti­gens against the BA.4/BA.5 Omi­cron sub­vari­ant strains and is part of Mod­er­na’s ef­fort to de­liv­er a boost­er shot this au­tumn, pend­ing the nec­es­sary go-ahead from the FDA and CDC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.